Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008:2:102.
doi: 10.3332/ecancer.2008.102. Epub 2008 Nov 24.

Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma

T De Pas  1 , G Spitaleri, P D Vigna, F Toffalorio, G Curigliano, A Gambino, S Boselli, C Catania, F de Braud
Affiliations
Case Reports

Gemcitabine-induced progressive and sustained tumour response in a patient with multi-drug resistant uterine leiomyosarcoma

T De Pas et al. Ecancermedicalscience. 2008.

Abstract

Background: despite the fact that the combination of gemcitabine (GCB) and docetaxel shows an increased benefit for disease-free survival and overall survival compared to GCB alone in patients with soft-tissue sarcoma, GCB mono-chemotherapy should be considered as a preferable option with respect to the combination because of its lower toxicity profile and the possibility of it being administered continuously for a long time period.

Case report: we report a clinical case of a woman with advanced high-grade uterine leiomyosarcoma, refractory to ifosfamide, doxorubicin and trabectedin, who experienced a sustained and progressive response to GCB alone.

Conclusions: GCB given as mono-chemotherapy can obtain long-lasting tumour control in patients heavily pre-treated with various chemotherapeutic regimes for uterine LMS and should be considered as a possible option for this subset of patients.

Keywords: Gemcitabine; refractory uterine leiomyosarcoma; second-line chemotherapy.

PubMed Disclaimer

Figures

Figure 1a–c
Figure 1a–c
Figure 2a–c
Figure 2a–c
Figure 3a–c
Figure 3a–c
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Look KY, Sandler A, Blessing JA, Lucci JA, 3rd, Rose PG. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecol Oncol. 2004;92:644–7. doi: 10.1016/j.ygyno.2003.11.023. - DOI - PubMed
    1. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31. doi: 10.1200/JCO.2002.11.050. - DOI - PubMed
    1. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol. 2007;25:2755–63. doi: 10.1200/JCO.2006.10.4117. - DOI - PubMed
    1. Bay JO, Ray-Coquard I, Fayette J, et al. Groupe Sarcome Français. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer. 2006;119:706–11. doi: 10.1002/ijc.21867. - DOI - PubMed
    1. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. 2007;12:999–1006. doi: 10.1634/theoncologist.12-8-999. - DOI - PubMed

Publication types

LinkOut - more resources